Provectus Biopharmaceuticals Inc.

351 articles about Provectus Biopharmaceuticals Inc.

• Provectus Establishes Australian Subsidiary

  7/14/2016

• Provectus Announces PV-10 Data Discussed At 6th European Post-Chicago Melanoma/Skin Cancer Meeting

  7/13/2016

• Provectus Announces Acceptance Of Abstract For Poster Presentation At European Society For Medical Oncology 2016 Congress

  7/12/2016

• ASCO2016: ProvectusAnnounces Poster Presentation On PV-10 At Annual Meeting Of American Society Of Clinical Oncology Now Available Online

  6/9/2016

• ProvectusAnnounces Publication Of Article On PV-10 For In-Transit Melanoma In Journal Of Surgical Oncology

  6/8/2016

• BIO2016: Provectus Will Present At 2016 BIO International Convention In San Francisco, CA

  6/7/2016

• Provectus Launches Newly Redesigned Website And Official Facebook Page

  6/1/2016

• Provectus Announces Abstract Available On PV-10 Plus Radiotherapy In Melanoma

  5/20/2016

• Provectus Announces Abstract Available Online Of Trials In Progress; Abstract For Poster Presentation At ASCO Annual Meeting

  5/19/2016

• Provectus Announces Publication Of Article In Oncotarget Detailing PV-10’s Immuno-Ablative Mechanism Of Action

  5/13/2016

• Provectus Reports First Quarter 2016 Financial Results

  5/11/2016

• Provectus Will Hold Its 2016 First Quarter Business Update Conference Call On Tuesday, May 10, 2016, At 4 Pm Eastern Daylight Time

  5/4/2016

• Provectus Announces Publication Of Two Abstracts On Research Into IL PV-10 For Melanoma In Special Issue Of ANZ Journal Of Surgery

  4/28/2016

• Provectus To Participate In Panel At Third International Conference On The Progress Of Regenerative Medicine And Its Cultural Impact

  4/27/2016

• Provectus Reports Data On PV-10 In Combination Therapy And T Cell Mediated Immunity Presented At AACR Annual Meeting 2016

  4/22/2016

• Provectus Reports Trials In Progress Abstract Accepted For Poster Presentation At ASCO Annual Meeting

  4/21/2016

• Provectus Reports Fourth Quarter And Year End 2015 Financial Results

  3/31/2016

• Provectus To Host Its Quarterly Year-End 2015 Financial Business Update Conference Call Wednesday, March 30, 2016 At 4 Pm (EDT)

  3/24/2016

• Provectus Announces Abstract Publicly Available For Poster Presentation On PV-10 In Combination Therapy And T Cell Mediated Immunity

  3/18/2016

• Provectus Amends Protocol For Phase 3 Study Of PV-10 In Treatment Of Locally Advanced Cutaneous Melanoma

  3/16/2016